Second-line afatinib vs erlotinib for patients with squamous cell
carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and
serum biomarkers and long-term responders
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2017
Συγγραφείς:
Gadgeel, S. M. Soria, J. C. Felip, E. Cobo, M. Lu, S. and Syrigos, K. Lee, K. H. Goker, E. Georgoulias, V. Li, W. Guclu, S. Isla, D. Ardizzoni, A. Dupuis, N. and Gibson, N. Kraemer, N. Buehnemann, C. Solca, F. and Ehrnrooth, E. Goss, G.
